Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CFO’ operating in the Biopharma space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Shaun Holt
CFO of Berkeley Lights
Shaun joined Berkeley Lights in November 2015 and was appointed Chief Financial Officer in March 2016. Prior to becoming CFO, Shaun was Vice President of Finance. Prior to joining Berkeley Lights, Shaun spent 7 ½ years at Illumina, Inc. heading up various aspects of their Finance organization. His roles included Sr. Director, Global Head of R&D and Business Unit Finance, EMEA Head of Finance, Accounting and Facilities, and Commercial FP&A. He earned a B.S. in Finance from California State University, Stanislaus.
Follow Shaun Holt:
About Berkeley Lights: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Brian Piper
Chief Financial Officer of Prelude Therapeutics
Brian Piper joined Medgenics as VP, Finance and Investor Relations in April 2014. Prior to joining Medgenics, Mr. Piper served as Senior Director, Strategic Investment Group (SIG), for Shire Pharmaceuticals, LLC from 2010 to 2013, as well as several different finance and business development roles with Shire over the past 13 years. Mr. Piper began his affiliation with Shire in 2002 as Director of Finance for Shire’s North American Development group in Rockville, MD. In 2004 he established Shire’s first US Investor Relations group, based out of Philadelphia. After three years running US Investor Relations, Mr. Piper transitioned to an alliance management role and spent two years overseas in Dublin, Ireland helping establish geographic expansion strategies. Prior to joining Shire, Mr. Piper held strategic planning roles for Celera Genomics, was Controller for a start-up Contract Research Organization, and worked as a program planner and financial analyst for Otsuka Pharmaceuticals, Inc. Mr. Piper received a B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.
Follow Brian Piper:
About Aevi Genomic Medicine, Prelude Therapeutics, Scorpion Therapeutics: Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.
Howard Horn
CFO of Vir Biotechnology
Howard Horn is the Chief Financial Officer of VIR. Previously, he led the Financial Planning and Corporate Finance functions at Biogen. Prior to joining Biogen, he held positions of increasing responsibility and was focused on the life sciences as a consultant with McKinsey & Company and as an equity research analyst at UBS. Howard holds an M.B.A from the Wharton School of the University of Pennsylvania and a B.A in Economics from Princeton University.
Follow Howard Horn:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Karen Adams
CFO of Arrivo BioVentures LLC
Karen Adams has a 30 year career as a finance professional working with companies across a broad range of industries with the last 15 years focused on life sciences and technology. After starting her career as an Internal Auditor with International Paper Company, Inc., Karen Adams has held financial leadership positions with companies in software, professional services and biotechnology industries. Most recently, Karen Adams has been part of the management team, in the CFO role, responsible for the creation and sale of two companies (Addrenex Pharmaceuticals to Shionogi Pharma and Neuronex to Acorda Therapeutics) and Aerial BioPharma’s ADX-N05 asset sale to Jazz Pharmaceuticals. While Karen Adams life sciences experience has been primarily focused on early-stage, privately funded companies she was brought on as Assistant Controller at Millennium Pharmaceuticals, Inc. during its merger with COR Therapeutics – among the largest such mergers in the history of the biotech industry at that time. After Millennium Pharmaceuticals, Karen Adams went on to work with several early stage biotechnology ventures including Surface Logix, Inc., Compound Therapeutics, Inc., Galenea Corporation, BG Medicine, Inc., and Micell Technologies, Inc. Karen Adams contribution was concentrated on the creation of dynamic, integrated financial forecasting models as well as the implementation of core business structure. Karen Adams graduated from Boston College earning a BS in Management, majoring in Finance.
Follow Karen Adams:
About Arrivo BioVentures LLC, Emergo Therapeutics, KJA Associates, QuatroBio: Arrivo BioVentures is a pharmaceutical development company which focuses on identifying biologics and molecules to improve patient care.
Karen Adams
CFO of Arrivo BioVentures LLC
Karen Adams has a 30 year career as a finance professional working with companies across a broad range of industries with the last 15 years focused on life sciences and technology. After starting her career as an Internal Auditor with International Paper Company, Inc., Karen Adams has held financial leadership positions with companies in software, professional services and biotechnology industries. Most recently, Karen Adams has been part of the management team, in the CFO role, responsible for the creation and sale of two companies (Addrenex Pharmaceuticals to Shionogi Pharma and Neuronex to Acorda Therapeutics) and Aerial BioPharma’s ADX-N05 asset sale to Jazz Pharmaceuticals. While Karen Adams life sciences experience has been primarily focused on early-stage, privately funded companies she was brought on as Assistant Controller at Millennium Pharmaceuticals, Inc. during its merger with COR Therapeutics – among the largest such mergers in the history of the biotech industry at that time. After Millennium Pharmaceuticals, Karen Adams went on to work with several early stage biotechnology ventures including Surface Logix, Inc., Compound Therapeutics, Inc., Galenea Corporation, BG Medicine, Inc., and Micell Technologies, Inc. Karen Adams contribution was concentrated on the creation of dynamic, integrated financial forecasting models as well as the implementation of core business structure. Karen Adams graduated from Boston College earning a BS in Management, majoring in Finance.
Follow Karen Adams:
About Arrivo BioVentures LLC, Emergo Therapeutics, KJA Associates, QuatroBio: Arrivo BioVentures is a pharmaceutical development company which focuses on identifying biologics and molecules to improve patient care.
David Socks
Co-founder, CFO, and CBO of HilleVax
Follow David Socks:
About HilleVax, Phathom Pharmaceuticals: HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
David Wood
CFO of ESSA Pharma
David Wood has been CFO of ESSA since October 2013. He is responsible for managing all financial aspects of ESSA’s business and matters related to compliance and corporate governance. David has over 30 years of experience in management of both large and early stage companies in North America and the U.K. From 2003 to 2013, he was Head of Finance, Secretary and Treasurer at Celator Pharmaceuticals Inc. Prior to 2003, he was Managing Director of Cubist Pharmaceuticals (UK) Ltd., and Finance Director at TerraGen Discovery, Inc. During 18 years in the biopharmaceutical industry, David has overseen several M&A transactions and numerous financings, raising over $100 million. David began his career in the finance and exploration departments of Chevron Corp. He received a B.Sc. in Biology from Queen’s University, an M.B.A. from University of Western Ontario and holds a CPA, CMA accounting designation. He served on the governing body of the National Research Council of Canada from 2008 to 2014.
Follow David Wood:
About ESSA Pharma: ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Diane Marcou
Consulting CFO of Satellite Bio
Ms. Marcou has provided financial and strategic advisory services to a number of venture-backed technology companies, including ByAllAccounts, Inc., Fluidnet Corporation, Radianse and T2 Biosystems. Prior to working as an independent financial consultant, she was Chief Financial Officer and Vice President of Finance and Administration for Incentive Systems (dba Centive), a privately held venture-funded software company, and Chief Financial Officer at Workgroup Technologies, a publicly traded software company with domestic and international operations. Ms. Marcou earned a B.S. in Business Administration from Boston College, and her CPA from PricewaterhouseCoopers, formerly Coopers & Lybrand.
Follow Diane Marcou:
About Boston MicroFluidics, Cytrellis Biosystems, Incentive Systems, Satellite Bio, Workgroup Technology: Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.
Alexander Casdin
Chief Operating Officer & Chief Financial Officer of Epirium
Alexander Casdin is the Chief Financial Officer (CFO) of Epirium Bio. He has broad financial and operational expertise, with more than 20 years of experience as a healthcare executive and investor. Prior to joining Epirium, Mr. Casdin was founder, Chief Executive Officer (CEO) and portfolio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as CFO of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Mr. Casdin was a founder and senior advisor at Casdin Advisors, LLC; CEO and portfolio manager at Cooper Hill Partners, LLC, a healthcare investment fund; and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the Dreyfus Corporation as a senior managing analyst covering pharmaceuticals, biotechnology and medical devices. Mr. Casdin has been on the board of directors for multiple life science companies including Erasca, Inc., Dusa Pharmaceuticals, Inc., and Ignyta, Inc. Mr. Casdin received an M.B.A from Columbia Business School and a B.A. in political science from Brown University.
Follow Alexander Casdin:
About Epirium, Epirium: Epirium Bio is a clinical stage bio pharmaceutical company.
Douglas Larson
Group Chief Financial Officer of Beyond Air
Douglas Larson is the Group Chief Financial Officer at Beyond Air.
Follow Douglas Larson:
About Beyond Air: Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections.
Peter Collum
Chief Financial Officer and Chief Business Officer of Pharnext
More than 17 years’ experience in healthcare investment banking focused on M&A, financing and business development transactions. Previously partner at MTS Health Partners for public and private life sciences companies both in the US and abroad, and worked in the healthcare investment banking group at Bank of America. Started at Roche as an engineer.
Follow Peter Collum:
About Pharnext: Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
Dave Lowrance
Chief Financial Officer of Savara Pharmaceuticals
David Lowrance has served as Savara’s Chief Financial Officer since November 2016. From September 2014 to October 2016, Mr. Lowrance served as the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals, a fully-integrated specialty pharmaceutical company with multiple marketed products in the CNS space. From April 2011 to September 2014, Mr. Lowrance served as the Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company that specializes in ophthalmic therapeutics, where he was responsible for overseeing all aspects of Acucela’s day-to-day operations, business development and growth endeavors, investor relations and corporate communications. While at Acucela, Mr. Lowrance helped lead a $162 million international IPO, with a listing on the Tokyo Stock Exchange. From March 2003 to April 2011, Mr. Lowrance was Vice President and Chief Financial Officer of Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on commercializing branded prescription products, where he oversaw all aspects of finance and accounting, business and growth strategy and product development. Mr. Lowrance, a CPA, holds a B.B.A. in Accounting from the University of Georgia.
Follow Dave Lowrance:
About Savara Pharmaceuticals: Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection in cystic fibrosis.
David Dillman
CFO of Rev1 Ventures
Dave has responsibility for finance, operations, external reporting and human resources. He also serves as CFO for Rev1’s managed investment funds. Dave came to Rev1 after a career in corporate accounting with the holding company of Alamo, Enterprise and National Car Rental. He’s a skier and mountain biker, who is waiting for our entrepreneurs to invent the transporter so he can teleport back home to Montana for the weekends. Dave has a BS in Accounting from the University of Montana and is an Ohio licensed CPA.
Follow David Dillman:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Jeffrey Poulton
Chief Financial Officer of Shire
Jeffrey “Jeff” brings to the Board his financial, commercial and strategic acumen. Since joining Shire in 2003 he has held leadership positions in finance supporting the Neuroscience, Gastrointestinal and Rare Diseases business units as well as the positions of Interim Chief Financial Officer and Head of Investor Relations. In addition, Jeff oversaw the operations of the Rare Diseases business unit in North America, Latin America and Asia Pacific, as well as leading the integration of the legacy-Viropharma rare disease products into the Shire portfolio. Prior to joining Shire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety of corporate finance and business development roles, in addition to serving as a commissioned officer in the U.S. Navy. He received a Bachelor of Arts in Economics from Duke University and a Master of Business Administration in Finance from the Kelly School of Business at Indiana University.
Follow Jeffrey Poulton:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Kam Unninayar
CFO of Tetraphase Pharmaceuticals
Follow Kam Unninayar:
About Tetraphase Pharmaceuticals: Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
Kaitlyn Arsenault
Chief Financial Officer of Skye Bioscience
Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors.
Follow Kaitlyn Arsenault:
About Skye Bioscience: Skye Bioscience is a biopharmaceutical company focused on the discovery, development, and the commercialization.
Jeremy Hux
CFO of Manus Bio
Jeremy Hux currently works as Chief Financial Officer at Manus Bio.
Follow Jeremy Hux:
About Manus Bio, Marathon Capital: Manus Bio makes nature accessible and affordable for a growing society.
David Hastings
Chief Financial Officer of Arbutus Biopharma
David C. Hastings has served as a member of Entasis Therapeutics’s board of directors since April 2018. Mr. Hastings served as the Senior Vice President and Chief Financial Officer of Unilife Corporation from February 2015 to June 2017 and as Unilife’s Chief Accounting Officer and Treasurer from July 2016 to June 2017. From October 2003 to October 2014, Mr. Hastings served as Executive Vice President and Chief Financial Officer at Incyte Corporation. Mr. Hastings currently serves on the board of directors of Scynexis Inc. and VBL Therapeutics Ltd. Mr. Hastings received his B.A. in Economics at the University of Vermont.
Follow David Hastings:
About Arbutus Biopharma: Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Jeffrey H. Cooper
Chief Financial Officer of Humanigen
Follow Jeffrey H. Cooper:
About Humanigen, Sierra Oncology: Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
Cameron Durrant
Chairman, CEO and Interim CFO of Humanigen
Follow Cameron Durrant:
About Humanigen: Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
Jeffrey Fryer
Co-Founder & CFO of Rallybio
Jeff Fryer is the Co-Founder & Chief Financial Officer at Rallybio.
Follow Jeffrey Fryer:
About Rallybio: Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.
Bob McNamara
Executive Vice President, Chief Financial Officer of LDR Holding
Bob McNamara is Executive Vice President, Chief Financial Officer. He has over twenty years experience within technology environments including medical device and software. His experience includes managing two IPO’s including Accuray Inc. ($330 million) and Somnus ($50 million). He also served as a board member post IPO for Northstar Neurosciences. During his CFO career, Bob managed six acquisitions or mergers including the acquisition of InDefense, Inc. by Microsoft Corp., the acquisition of Recourse Technologies by Symantec, and was part of the team that negotiated the $1.1B acquisition of Target Therapeutics by Boston Scientific. He holds an MBA from University of Pennsylvania’s Wharton School and a BS from University of San Francisco. Bob is a Certified Public Accountant (non-practicing) and the former Mayor of Menlo Park, California.
Follow Bob McNamara:
About LDR Holding: LDR Global Home develops and commercializes systems and instrumentation used in spine treatments and surgeries.
James Matthew
President, Chief Executive Officer and Chief Financial Officer of Nanotherapeutics
Mr. Matthew joined the Nanotherapeutics Board of Directors in February 2008 and became the Chief Financial Officer of the Company in March 2011. Mr. Matthew is a member of the Board of Managers of NANO ADM, LLC, a wholly-owned subsidiary of the Company. He became President and Chief Executive Officer in May 2016. Mr. Matthew has over 30 years of financial experience, including more than 10 years as the Chief Financial Officer of public and private companies with responsibilities for accounting, finance, information management, investor relations, procurement and facility services. In addition, he has 20 years of experience with KPMG where he was responsible for a variety of transactions and financings for the Health Care and Life Sciences Industry Group. Mr. Matthew received an MBA from Michigan State University and a B.S. in Accountancy from the University of Illinois at Springfield.
Follow James Matthew:
About Nanotherapeutics: Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities,
Jay File
Chief Financial Officer of Evofem Biosciences
Jay File has served as our Chief Financial Officer at Evofem Biosciences since 2015. He has approximately 25 years of diverse accounting and finance experience within a variety of both public and private biotechnology companies. Most recently, he provided executive financial and accounting oversight services to various biotechnology companies in San Diego, assisting in their initial public offering process and helping to establish and improve their accounting and finance operations as publicly-traded entities. Prior to this, Mr. File was Senior Director and Controller of Sequenom, Inc, a diagnostic company that developed and commercialized molecular diagnostics testing services for the women’s health market. During that time, he served as Treasurer of their diagnostic subsidiary and providing assistance in the raise of over $400 million in combined equity and convertible note offerings. He also assisted in the commercial launch of four diagnostic tests in a two-year period, which included Sequenom’s revolutionary noninvasive prenatal test for Down syndrome. Earlier in his career he worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP, where he worked with a variety of clients assisting with attestation and periodic reporting requirements, public offerings and acquisitions. He graduated from Central Washington University with a Bachelor’s of Science in Accounting and International Business and is a Certified Public Accountant (inactive).
Follow Jay File:
About Evofem Biosciences, WCG Cares: Evofem is a biotechnology company that develops reproductive and contraceptive care products for women worldwide.
Ryan Martins
Chief Financial Officer of 89bio
Ryan Martins is chief financial officer at 89bio.
Follow Ryan Martins:
About 89bio: 89Bio is a biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders.
C. Evan Ballantyne
Chief Financial Officer of OncXerna Therapeutics
C. Evan Ballantyne is the chief financial officer of [Agenus](https://www.crunchbase.com/organization/agenus), a biotechnology company that develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. Previously, he worked as the CEO of Synthetic Biologics. Ballantyne served as the CFO and executive vice president of Trovis Pharmaceuticals from 2006, before which he was the CFO of Knowledge Impact, ZymeQuest, Clinical Data, Velico Medical, Avalon Pharmaceuticals, and AcNielsen Corporation. Ballantyne holds a bachelor’s degree in political sciences and American history from the University of Western Ontario and a post-graduate degree in business administration from the University of Windsor.
Follow C. Evan Ballantyne:
About OncXerna Therapeutics: OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
John Borgeson
Chief Financial Officer of ALX Oncology
John Borgeson is our Chief Financial Officer and has served in this position since June 2014. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. Previously Borgeson was a Vice President of Finance at Pfizer and a member of Pfizer’s Global Financial Leadership Team. Borgeson’s roles at Pfizer included CFO for Pfizer’s biotherapeutics division and corporate tax executive with responsibility for US and Europe. Under Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies. Borgeson has more recently led finance for a variety of private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Follow John Borgeson:
About ALX Oncology, Kodiak Sciences: ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Benjamin Newmark
President & CFO of SolasCure
Benjamin Newmark is the Founder, President, and CFO at SolasCure.
Follow Benjamin Newmark:
About Better.com, SolasCure: Solascure is a biotechnology company focused on the development of fit for purpose, efficacious wound care products.
James Cerveaux
Chief Financial Officer of CDx Diagnostics
Jimmy Cerveaux brings C-level executive experience with deep financial expertise acquired at blue chip companies and as an entrepreneur. He co-founded, led and sold Unicity Eldercare, a successful 150 employee healthcare company located in NY & NJ. Mr. Cerveaux also worked for many years as an Auditor and a Mergers & Acquisitions Consultant at Ernst & Young, and as an equity analyst for a leading investment management firm in the Middle East. He is a graduate of Massachusetts Institute of Technology in Cambridge, MA.
Follow James Cerveaux:
About CDx Diagnostics: CDx Diagnostics develops and provides diagnostic systems intended to prevent cancer by detecting pre-cancerous cells.
Richard Vellacott
Chief Financial Officer of Horizon Discovery
Richard has over 15 years’ experience as a chartered accountant, working with life science companies from start-ups to global pharmaceuticals. He also has a first class degree in biological sciences from Durham University. Past roles include Vice President, Finance at CSR plc, a listed hi-tech company with revenues of $1bn. During his time at CSR Richard had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of a NASDAQ listed Zoran Corp., product portfolio management, R&D budgeting and business investment / divestment decisions. Before this, Richard was a Director in Deloitte’s life sciences practice, where he specialized in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets. Beyond his corporate responsibilities, Richard has advised the EC on funding for life science companies and presented at investor conferences and technical seminars on financial issues facing the life science industry.
Follow Richard Vellacott:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Olivia K. Bloom
CFO, Treasurer & EVP of Geron
Olivia K. Bloom is the chief financial officer, treasurer, and executive vice president of [Geron](https://www.crunchbase.com/organization/geron-corp#/entity), a biopharmaceutical company that discovers and develops therapeutic products for cancer. Before joining Geron, she started her career in public accounting at KPMG Peat Marwick and became a certified public accountant in 1994. Bloom holds a bachelor’s degree in business administration from the University of California, Berkeley.
Follow Olivia K. Bloom:
About Geron: Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,
Howard Liang
President and CFO of Tessera Therapeutics
Follow Howard Liang:
About Tessera Therapeutics: Tessera Therapeutics is an early-stage life sciences company.
Manmeet S. Soni
Chief Financial Officer of Reata Pharmaceuticals
CFO/EVP at Reata Pharmaceuticals.
Follow Manmeet S. Soni:
About Reata Pharmaceuticals, Reata Pharmaceuticals: Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Shalin Y. Shah
CFO of Marius Pharmaceuticals
Shalin Y. Shah is the CFO at Marius Pharmaceuticals. He is also the director of private investments at Shah Capital. Shalin holds a BS degree in finance from Rutgers, The State University of New Jersey-New Brunswick.
Follow Shalin Y. Shah:
About Marius Pharmaceuticals: Marius Pharmaceuticals is a biopharmaceutical company that brings novel treatments to a range of diseases with unmet medical needs.
Marc Schneebaum
Chief Financial Officer of Avalyn Pharma
Follow Marc Schneebaum:
About Avalyn Pharma: Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis.
John Leaman
CFO of Aevi Genomic Medicine
John Leaman joined Medgenics as CFO in September 2013. Prior to joining Medgenics, Dr. Leaman served as VP of Commercial Assessment at Shire plc, a global specialty pharmaceutical company, with responsibility for the strategic assessment of licensing and M&A opportunities, including Shire’s acquisition of SARcode Bioscience Inc. Prior to joining Shire in 2011, from 2007 to 2011, Dr. Leaman was a Principal at Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies, where he oversaw the fund’s investment and corporate board duties in life science investments including Proteon Therapeutics, Inc., Inotek Pharmaceuticals Corp., ZS Pharma, Inc. and MicuRx Pharmaceuticals, Inc. Prior to that, he was an Associate Principal at McKinsey & Company, where he provided consulting services to senior management of several top 20 pharmaceutical companies including M&A and corporate finance, payer/reimbursement strategies and strategic product development. He received an M.D. and an M.B.A. from the University of Pennsylvania’s School of Medicine and Wharton School, respectively. He received a degree in Psychology, Philosophy and Physiology at Oriel College, University of Oxford, while completing a Rhodes scholarship. Dr. Leaman received a B.S. in biology from Elizabethtown College.
Follow John Leaman:
About Aevi Genomic Medicine: Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies.
Eric Shaff
CFO of Seres Therapeutics
Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. He serves as the executive vice president and chief financial officer of [Seres Therapeutics](https://www.crunchbase.com/organization/seres-health#/entity), a therapeutics company engaged in the R&D of drugs for the treatment of microbiome diseases. Previously, Shaff was vice president of corporate finance at Momenta Pharmaceuticals, where he helped manage Momenta Pharmaceutical’s accounting, finance, planning, and procurement functions as well as contributing to Momenta Pharmaceutical’s investor relations efforts. Prior to joining Momenta Pharmaceuticals, he was the vice president of finance at Genzyme’s Rare Genetic Disease Division. Shaff held several positions in business unit finance, corporate finance, and corporate development at Genzyme. Before joining Genzyme, he worked in corporate finance at Pfizer and worked in investment banking for Broadview International. Shaff obtained his bachelor’s degree in political science and economics from the University of Pennsylvania and his MBA in finance from the Johnson Graduate School of Management at Cornell University.
Follow Eric Shaff:
About Seres Therapeutics: Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products.
Ryan Confer
Chief Financial Officer of Genprex
Ryan M. Confer was Business Manager of the Company. From December 2013 through September 2016, he served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business Manager. Mr. Confer has served us in a variety of strategic, operations, and finance capacities since our inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as VP of Customer Experience and then later as VP of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin’s IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.
Follow Ryan Confer:
About Confer Capital, Genprex, Gurnade, Inc.: Genprex is a clinical-stage biopharmaceutical company developing revolutionary immunogene therapies for cancer.
Daniel Gutschenritter
Chief Financial Officer of MedMark Treatment Centers
Dan Gutschenritter is EVP & Chief Financial Officer of BayMark Health Services,. Dan joined MedMark Services as Chief Financial Officer in October 2012. He has over twenty years of experience in the fields of finance and operations management. Priorto MedMark, Dan had been the Chief Financial Officer for Medical Clinic of North Texas, P.A. (MCNT). Other roles include serving as the Chief Financial Officer and Administrative Officer of Partners Imaging LP, a company which developed and managed imaging joint ventures with physician groups. Dan has extensive experience working in both public and private equity backed organizations having raised in excess of $350 million in new capital over the course of his career. Dan received his MBA from the Fuqua School of Business at Duke University and completed his undergraduate work at the University of Wisconsin.
Follow Daniel Gutschenritter:
About BayMark Health Services, MedMark Treatment Centers: MedMark Treatment Centers is a pharmacy company that provides specialized pharmacy care to patients with unique or chronic medication.
Stan Musial
Chief Financial Officer of Egalet
Mr. Musial has served as our chief financial officer since April 2013. From June 2011 to March 2013, Mr. Musial was self-employed, acting as an independent consultant in the fields of financial management and accounting services. From January 2005 to May 2011, Mr. Musial served as chief financial officer of Prism Pharmaceuticals, Inc., a specialty pharmaceutical and drug development company. Prior to joining Prism Pharmaceuticals, Mr. Musial was vice president, finance, and chief financial officer for Strategic Diagnostics, Inc., a publicly held biotechnology company, from 2002 to 2004. Mr. Musial began his career with KPMG LLP, a professional services company. Mr. Musial received a B.S. in accounting from the Pennsylvania State University and an M.B.A. from Temple University. He is a certified public accountant in the Commonwealth of Pennsylvania.
Follow Stan Musial:
About Egalet: Egalet is a specialty pharmaceutical company that develops pain management products.
Stan Musial
Chief Financial Officer of Egalet
Mr. Musial has served as our chief financial officer since April 2013. From June 2011 to March 2013, Mr. Musial was self-employed, acting as an independent consultant in the fields of financial management and accounting services. From January 2005 to May 2011, Mr. Musial served as chief financial officer of Prism Pharmaceuticals, Inc., a specialty pharmaceutical and drug development company. Prior to joining Prism Pharmaceuticals, Mr. Musial was vice president, finance, and chief financial officer for Strategic Diagnostics, Inc., a publicly held biotechnology company, from 2002 to 2004. Mr. Musial began his career with KPMG LLP, a professional services company. Mr. Musial received a B.S. in accounting from the Pennsylvania State University and an M.B.A. from Temple University. He is a certified public accountant in the Commonwealth of Pennsylvania.
Follow Stan Musial:
About Egalet: Egalet is a specialty pharmaceutical company that develops pain management products.
Ted Myles
Executive Vice President and Chief Financial Officer of AMAG Pharmaceuticals
Ted Myles joined ACT in June 2013, as the company’s Chief Financial Officer and Executive Vice President of Corporate Development. From November 2008 to June 2013 Ted Myles was with PrimeraDx, a privately-held molecular diagnostics company, where he served as Chief Financial Officer and Vice President of Operations. At PrimeraDx, Ted Myles helped to lead the company from the proof-of-concept stage to become a fully integrated commercial organization. Prior to joining PrimeraDx, Ted Myles was the Chief Financial Officer and Senior Vice President of Finance at Pressure BioSciences, a Nasdaq-listed, life-science tools company. Earlier in his career, Ted Myles held financial positions of increasing responsibility with EMD Pharmaceuticals (a subsidiary of Merck KGaA), SG Cowen Securities Corporation, Boston Biomedica and PriceWaterhouseCoopers. He received a master’s degree in business administration, with an emphasis on strategy and corporate finance, from Washington University in St. Louis and a bachelor’s degree in business administration from the University of Hartford. Ted Myles became a CPA in 1996.
Follow Ted Myles:
About AMAG Pharmaceuticals: AMAG Pharmaceuticals is a biopharmaceutical company, which utilizes the technology for the development and commercialization of therapeutic.
Molly Henderson
Chief Financial Officer of UroGen Pharma
Molly Henderson is the Chief Financial Officer at UroGen Pharma.
Follow Molly Henderson:
About UroGen Pharma: UroGen Pharma is a clinical-stage biopharmaceutical company.
Joel Sussman
Chief Financial Officer of Immunome
Joel Sussman is a financial management consultant who serves in the capacity of CFO for early-stage companies including Garnet BioTherapeutics. His present and former clients include numerous venture capital-backed life sciences companies as well as companies in the fields of information technologies and services. Before beginning his consulting practice in 1995, he had fifteen years experience as Chief Financial Officer and/or Treasurer of public and private technology and healthcare companies. In 1997, he joined a client, CDNow, Inc., as CFO and took it public, resuming his consulting practice in 2001 after its sale to Bertelsmann AG. Mr. Sussman began his career as a banker and has an undergraduate degree from Yale University, an MBA degree from the Wharton School of the University of Pennsylvania, and is a licensed Certified Public Accountant in Pennsylvania.
Follow Joel Sussman:
About Galera Therapeutics, Immunome, PhaseBio Pharmaceuticals: Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery.
Daniel Clark
Interim Chief Financial Officer of Kiromic Biopharma
On September 30, 2021, the Board of Directors of the Company appointed Dan Clark as interim Chief Financial Officer, effective September 30, 2021. Mr. Clark joined the Company in February 2020 and served as the Company’s Corporate Controller until September 2021, when he was promoted to Vice President – Finance Operations prior to his appointment as interim Chief Financial Officer. Before joining the Company, Mr. Clark was a Manager with The Siegfried Group, a national accounting services firm, from June 2018 to February 2020. Prior to his employment with The Siegfried Group, Mr. Clark served as Senior Consultant – Office of the CFO Solutions for FTI Consulting, a global financial consulting firm, from January 2017 to May 2018. Prior to that, Mr. Clark was Senior Associate – Audit at KPMG US, a member of Big Four global accounting firm KPMG, from August 2011 to June 2015.
Follow Daniel Clark:
About Kiromic Biopharma: Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.
Donald J. Griffith
Chief Financial Officer of Outlook Therapeutics
Follow Donald J. Griffith:
About Outlook Therapeutics: Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.
Lawrence A. Kenyon
Chief Financial Officer of Outlook Therapeutics
Lawrence A. Kenyon is the Chief Financial Officer of Outlook Therapeutics.
Follow Lawrence A. Kenyon:
About Outlook Therapeutics: Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.
Ola Soderquist
CFO/Controller & Co-founder of Oxygen Therapy
Follow Ola Soderquist:
About Oxygen Therapy: Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.
John Trainer
Chief Financial Officer of NexImmune
John Trainer is the Chief Financial Officer at NexImmune.
Follow John Trainer:
About NexImmune: NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.
Gregory Wilson
Consulting CFO of Cleave Therapeutics
Follow Gregory Wilson:
About Cleave Therapeutics: Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.
